I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $227.12M |
||||
Company | Location | Date | Amt. (M) | Details |
| | ||||
Amphora | Research Triangle | 12/17 | $23 | Amphora raised $23M in a Series B round co-led by ARCH Venture Partners, MPM Capital, Venrock Associates, CW Group and Versant Ventures |
| ||||
Angiogenix | Burlingame, | 12/18 | $12 | Angiogenix raised $12M in a second-round financing led by BioAsia Investments LLC; other investors were Teknoinvest Management A/S, AIG Global Investment Corp., Posco BioVentures, Kenson Ventures LLC, Asset Management Co. and Sunflower Capital Partners |
| ||||
BioRexis | King of Prussia, Pa. | 12/19 | $8 | BioRexis raised $8M in a Series A financing with investors Tullis-Dickerson & Co. Inc., ProQuest Investments and Quaker BioVentures |
| ||||
Cytochroma | Markham, | 12/4 | C$6.5 (US$4.2) | Cytochroma raised an additional US$4.2M in a recent private equity financing, bringing the total raised in the Series B round to C$22M; investors were The VenGrowth Advanced Life Sciences Fund Inc., as well as other Canadian and Danish investors |
| ||||
Idun | San Diego | 12/9 | $22.8 | Idun raised $22.8M in a preferred stock private financing led by Ventana Capital Management; other investors were GeneChem, Hambrecht and Quist Capital Management LLC, RBC Capital Partners, Bio-Veda Capital, Sorrento Associates, Venrock Associates and ARCH Venture Partners; Fortis Bank served as the round's financial adviser |
| ||||
Intracel | Frederick, Md. | 12/12 | $16 | Intracel raised $16M in a first closing of its Series B convertible preferred stock offering led by MPM Capital |
| ||||
MaxCyte | Rockville, Md. | 12/18 | $1.75 | MaxCyte raised $1.75M in a Series A financing |
| ||||
METabolic | Clermont- | 12/4** | €6 | METabolic EXplorer raised US$6M in a second financing led by Credit Lyonnais Private Equity; other investors were SPEF Venture, Sofimac, Viveris Management and FPCR Gestion |
| ||||
Microbiotix | Toronto | 12/20 | C$0.5 | Microbiotix completed a US$322,111 principal amount 8% convertible debenture deal in a transaction with an existing shareholder |
| ||||
Paradigm | Cambridge, UK | 12/9 | 12 | Paradigm Therapeutics completed a second round of private equity funding led by BioMedical Sciences Investment Fund Pte. Ltd. and Techmark Medical Ventures; Avlar BioVentures Fund I and Fund II also invested, as did Genmab A/S |
| ||||
Pintex | Watertown, | 12/23 | $7.25 | Pintex raised $7.25M in a Series B round led by POD Holding and Zero Stage Capital; other investors were BioVentures Investors and Canaan Partners |
| ||||
QRxPharma | Boston and Brisbane, | 12/10 | $5 | QRxPharma completed a $5M Series A preferred stock financing led by Innovation Capital; other investors were Nanyang Ventures, SpringRidge Ventures and UniSeed |
| ||||
Renovo Ltd. | Manchester, UK | 12/2 | 21 | Renovo closed a second round of private equity financing led by HealthCap AB; other investors were Care Capital LLC, Atlas Venture and JPMorgan Partners |
| ||||
Targacept Inc. | Winston-Salem, | 12/5 | $46 | Targacept raised $46M in a financing led by Nomura International's Healthcare Private Equity Group; other investors were New Enterprise Associates, CDIB BioScience Ventures, Easton Hunt Capital Partners, EuclidSR Partners, Burrill & Co., Academy Venture Fund, Advent Venture Partners, Auriga Ventures, CDC-IXIS Innovation, Genavent Fund and Societe Generale Asset Management Finance |
| ||||
Transave Inc. | Monmouth | 12/20 | $12 | Transave raised $12M in a Series B financing led by Easton Hunt Capital Partners and ABN AMRO Capital; other investors were Techno Venture Management, Sycamore Ventures, CDIB Bioscience and Musket Research Associates |
| ||||
Vectura Ltd. | Bath, UK | 12/4 | 6.9 | Vectura raised US$10.8M in a financing round with investors The Merlin Biosciences Fund LP and ISIS Capital/ISIS Asset Management business units |
| ||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $42.5M |
||||
Company | Partner | Amt. | Triggering | Details (Date) |
|
| ||||
Aphton Corp. | Aventis SA | $3 | Investment | Aventis purchased a convertible, redeemable, five-year $3M interest-bearing debenture note from Aphton (12/20) |
| ||||
Applied | Chiron Corp. | ND | Milestone payment | Applied Molecular achieved the milestone through its collaboration with Chiron to optimize a non-antibody biotherapeutic candidate (12/18) |
| ||||
Atugen AG* | Altana Pharma | ND | Milestone payments | Atugen received two milestone payments from Altana as part of a validation alliance for new target molecules associated with cancer and diseases of the immune system (12/4) |
| ||||
Celltech | Pharmacia Corp. | $10 | Milestone payment | Celltech received the payment for the start of Phase III development of CDP 870 in rheumatoid arthritis (12/4**) |
| ||||
CombiMatrix | Roche Applied | $5.5 | Milestone payments | CombiMatrix received payments for hitting milestones in its collaboration for the development and commercialization of its DNA microarray technology (12/2) |
| ||||
Diversa Corp. | Syngenta AG | ND | Milestone payment | Diversa received a milestone payment for delivering several animal feed product candidates and promising leads for other applications (12/19) |
| ||||
Genaissance Pharmaceuticals Inc. (GNSC) | Johnson & Johnson | ND | Milestone payment | Genaissance received a milestone payment for demonstrating that the HAP Technology can be used to identify meaningful associ- ations between genetic variation and clinical observations (12/5) |
| ||||
Genencor International | Dow Corning | ND | Milestone payment | Genencor received an undisclosed payment after achieving milestones in the first year of an alliance to create a silicon biotechnology platform (12/12) |
| ||||
Immuno- | Sanofi- | €20 | Investment | Sanofi invested US$20M in Immuno-Designed as part of the co-development agreement of cellular immunotherapies and therapeutic vaccines for cancer (12/11**) |
| ||||
LION | Bayer AG | $2 | Milestone payment | LION received a $2M payment for delivering software components for a pharmacophore informatics project to enhance lead identification and optimization in drug discovery (12/18) |
| ||||
Pharmexa | H. Lundbeck A/S | ND | Milestone payment | Pharmexa received an undisclosed milestone payment after Lundbeck decided to take the project of AutoVac technology as it relates to Alzheimer's disease into the early development stage (12/10) |
| ||||
Sunesis Pharm- | Johnson & Johnson | ND | Milestone payment | Sunesis received a milestone payment by discovering and delivering a lead series of compounds to Johnson & Johnson (12/18) |
| ||||
Tripos Inc. | Undisclosed partner | $2 | Milestone payment | Tripos received more than $2M for work performed as a subcontractor with the partner company's enterprise informatics consulting business (12/18) |
|
| ||||
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Denotes privately held company. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange |
||||
